

# Sebastian Schneeweiss

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8414270/sebastian-schneeweiss-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

331  
papers

21,352  
citations

73  
h-index

138  
g-index

347  
ext. papers

24,664  
ext. citations

7.1  
avg, IF

7.19  
L-index

#	Paper	IF	Citations
331	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. <i>Annals of Internal Medicine</i> , <b>2022</b> , 175, W4-W5	8	
330	A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data.. <i>Clinical Epidemiology</i> , <b>2022</b> , 14, 601-608	5.9	0
329	Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1542-1551	6.7	3
328	Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 934-951	2.6	4
327	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <i>Endocrine Reviews</i> , <b>2021</b> , 42, 658-690	27.2	10
326	A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2021</b> , 4, e00237	2.7	0
325	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 805-816	5.1	2
324	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. <i>Diabetes Care</i> , <b>2021</b> , 44, 1774-1782	14.6	3
323	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1694-1695	6.7	
322	The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2502-2512	6.7	
321	Risk of connective tissue disease, morphea and systemic vasculitis in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 195-202	4.6	1
320	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 300-311	4.5	7
319	Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 273-280	3.8	1
318	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. <i>Circulation</i> , <b>2021</b> , 143, 1002-1013	16.7	52
317	Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. <i>Diabetes Care</i> , <b>2021</b> , 44, 826-835	14.6	19
316	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. <i>Journal of General Internal Medicine</i> , <b>2021</b> , 36, 2601-2607	4	0
315	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1453-1462	6.7	7

314	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 816-828	6.1	3
313	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2320-2328	6.7	2
312	Response by Franklin and Schneeweiss to Letters Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". <i>Circulation</i> , <b>2021</b> , 144, e162-e163	16.7	2
311	Validation of obesity-related diagnosis codes in claims data. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2623-2631	6.7	3
310	Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. <i>Health Technology Assessment</i> , <b>2021</b> , 25, 1-70	4.4	
309	Single-arm oncology trials and the nature of external controls arms. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 1052-1066	2.1	2
308	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1214-1223	8	11
307	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1528-1541	8	8
306	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , <b>2020</b> , 80, 1961-1972	12.1	13
305	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 350-357	6.1	16
304	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1337-1345	4.5	3
303	Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. <i>Clinical Epidemiology</i> , <b>2020</b> , 12, 607-616	5.9	6
302	External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research. <i>Clinical Epidemiology</i> , <b>2020</b> , 12, 133-141	5.9	6
301	Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. <i>Diabetes Care</i> , <b>2020</b> , 43, 921-924	14.6	30
300	Application of a Graphical Depiction of Longitudinal Study Designs to Managed Care Pharmacy Research. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 268-274	1.9	4
299	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 735-737	6.1	9
298	Improving measurement of binary covariates in claims data: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1093-1100	2.6	
297	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 342-345	5.1	10

296	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 874-884	6.1	1
295	Kim et al. Respond to "Estimation With Claims-Based Frailty Indexes". <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 373-374	3.8	
294	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , <b>2020</b> , 3, e1918962	10.4	81
293	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1405-1419	6.1	7
292	Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1151-1158	2.6	3
291	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, 463-473	8	32
290	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. <i>Value in Health</i> , <b>2020</b> , 23, 1128-1136	3.3	27
289	Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2497-2505	3	3
288	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 221-228	5.1	5
287	Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 817-826	6.1	31
286	Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 827-833	6.1	14
285	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 238-244	6.1	11
284	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 1513-1521	6.1	10
283	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 456-464	2.4	87
282	Theory meets practice: a commentary on VanderWeele's principles of confounder selection. <i>European Journal of Epidemiology</i> , <b>2019</b> , 34, 221-222	12.1	2
281	Real-World Evidence of Treatment Effects: The Useful and the Misleading. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 43-44	6.1	17
280	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005173	5.8	7
279	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 1156-1163	6.1	8

278	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. <i>Drug Safety</i> , <b>2019</b> , 42, 1355-1363	5.1	1
277	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. <i>Drug Safety</i> , <b>2019</b> , 42, 1287-1295	5.1	10
276	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. <i>Diabetes Care</i> , <b>2019</b> , 42, 2204-2210	14.6	50
275	Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective database studies". <i>Statistics in Medicine</i> , <b>2019</b> , 38, 4209-4212	2.3	9
274	Desmopressin and the risk of hyponatremia: A population-based cohort study. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002930	11.6	8
273	Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees. <i>Blood</i> , <b>2019</b> , 134, 2166-2166	2.2	
272	Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 1442-1452	1.9	6
271	Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 434-438	6.7	41
270	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 867-877	6.1	68
269	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 979-993	6.1	10
268	Scalable collaborative targeted learning for high-dimensional data. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 532-554	2.3	15
267	Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 1044-1063	2.3	15
266	Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. <i>Clinical Epidemiology</i> , <b>2019</b> , 11, 1-15	5.9	40
265	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 707-712	2.6	7
264	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 399-405	5.3	24
263	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 383-390	2.6	1
262	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 1008-1015	6.1	3
261	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. <i>Journal of Comparative Effectiveness Research</i> , <b>2018</b> , 7, 57-66	2.1	1

260	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 567-569	2.6	6
259	Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. <i>European Journal of Epidemiology</i> , <b>2018</b> , 33, 545-555	12.1	15
258	Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. <i>BMJ Open</i> , <b>2018</b> , 8, e019475	3	4
257	Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 1799-1807	3.8	25
256	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 899-905	6.1	19
255	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004684	5.8	3
254	Real-World Data Analytics Fit for Regulatory Decision-Making. <i>American Journal of Law and Medicine</i> , <b>2018</b> , 44, 197-217	0.5	10
253	Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 771-788	5.9	27
252	Association of Medicare® Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 178-187	7.4	10
251	"Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients". <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 95-104	2.6	1
250	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 974-984	6.7	46
249	Use of Health Care Databases to Support Supplemental Indications of Approved Medications. <i>JAMA Internal Medicine</i> , <b>2018</b> , 178, 55-63	11.5	70
248	Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004700	5.8	11
247	Using Previous Medication Adherence to Predict Future Adherence. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2018</b> , 24, 1146-1155	1.9	15
246	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 1361-1370	2.6	7
245	Virtual non-enhanced dual-energy CT reconstruction may replace true non-enhanced CT scans in the setting of suspected active hemorrhage. <i>European Journal of Radiology</i> , <b>2018</b> , 109, 218-222	4.7	3
244	Removal of ineligible outcome cases reduces confounding. <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 575-579	5.9	1
243	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1154-1164	9.5	119

242	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. <i>Drug Safety</i> , <b>2017</b> , 40, 923-932	5.1	10
241	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 200-209	1.7	15
240	Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 501-510	3.8	2
239	Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2300-2302	59.2	191
238	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 712-721	2.6	25
237	From Trial to Target Populations - Calibrating Real-World Data. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1203-1205	59.2	24
236	Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. <i>Drug Safety</i> , <b>2017</b> , 40, 169-181	5.1	12
235	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 613-625	2.1	2
234	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , <b>2017</b> , 20, 1003-1008	3.3	113
233	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1507-1512	2.6	13
232	Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 914-916	6.1	3
231	When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 924-933	6.1	119
230	Improved CT-detection of acute bowel ischemia using frequency selective non-linear image blending. <i>Acta Radiologica Open</i> , <b>2017</b> , 6, 2058460117718224	1.2	3
229	Posing Causal Questions When Analyzing Observational Data-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 201-202	27.4	
228	Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 474-478	3.8	5
227	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 651-657	3	17
226	Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. <i>Statistics in Medicine</i> , <b>2017</b> , 36, 1946-1963	2.3	49
225	Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 558-564	6.1	29

224	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2938-44	5.1	12
223	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2106-13	9.5	11
222	Improving therapeutic effectiveness and safety through big healthcare data. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 262-5	6.1	18
221	Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 147-59	6.1	34
220	Developing alerting thresholds for prospective drug safety monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 755-62	2.6	
219	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. <i>Journal of Clinical Epidemiology</i> , <b>2016</b> , 76, 200-8	5.7	16
218	"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 699-712	6.1	45
217	Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 633-646	6.1	34
216	Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 64-72	2.6	3
215	Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. <i>American Journal of Epidemiology</i> , <b>2015</b> , 182, 651-9	3.8	33
214	Assessing the relative efficacy of new drugs: an emerging opportunity. <i>Nature Reviews Drug Discovery</i> , <b>2015</b> , 14, 443-4	64.1	10
213	Methodological approaches to evaluate the impact of FDA drug safety communications. <i>Drug Safety</i> , <b>2015</b> , 38, 565-75	5.1	30
212	Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. <i>Drug Safety</i> , <b>2015</b> , 38, 589-600	5.1	5
211	Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. <i>Drug Safety</i> , <b>2015</b> , 38, 295-310	5.1	20
210	Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness. <i>Journal of the American Geriatrics Society</i> , <b>2015</b> , 63, 516-23	5.6	15
209	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , <b>2015</b> , 38, 1075-82	5.1	7
208	Stakeholder assessment of comparative effectiveness research needs for Medicaid populations. <i>Journal of Comparative Effectiveness Research</i> , <b>2015</b> , 4, 465-71	2.1	1
207	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1360-7	2.4	74

206	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1968-75	2.4	68
205	DECISION-MAKING ALIGNED WITH RAPID-CYCLE EVALUATION IN HEALTH CARE. <i>International Journal of Technology Assessment in Health Care</i> , <b>2015</b> , 31, 214-22	1.8	11
204	From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 97, 234-46	6.1	133
203	Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1277-89	7	97
202	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. <i>Statistics in Medicine</i> , <b>2015</b> , 34, 753-81	2.3	31
201	A unified framework for classification of methods for benefit-risk assessment. <i>Value in Health</i> , <b>2015</b> , 18, 250-9	3.3	15
200	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. <i>Value in Health</i> , <b>2015</b> , 18, 1063-9	3.3	3
199	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. <i>Value in Health</i> , <b>2015</b> , 18, 1057-62	3.3	3
198	Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. <i>Drug Safety</i> , <b>2014</b> , 37, 151-61	5.1	13
197	"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. <i>American Journal of Epidemiology</i> , <b>2014</b> , 180, 636-44	3.8	14
196	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): architecture. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2014</b> , 21, 615-20	8.6	59
195	Comparative mortality risks of antipsychotic medications in community-dwelling older adults. <i>British Journal of Psychiatry</i> , <b>2014</b> , 205, 44-51	5.4	58
194	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. <i>Computational Statistics and Data Analysis</i> , <b>2014</b> , 72, 219-226	1.6	60
193	Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS ONE</i> , <b>2014</b> , 9, e105376	3.7	27
192	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 1223-5	2.6	4
191	The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs. <i>American Journal of Epidemiology</i> , <b>2014</b> , 180, 847-52	3.8	17
190	Ensuring patient privacy in data sharing for postapproval research. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1644-9	59.2	8
189	Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 891-901	2.6	95

188	Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 830-8	2.6	6
187	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 619-27	2.6	20
186	Learning from big health care data. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2161-3	59.2	205
185	Metrics for covariate balance in cohort studies of causal effects. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1685-99	2.3	145
184	Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. <i>Diabetologia</i> , <b>2014</b> , 57, 2237-50	10.3	41
183	Patients' preferences in anticoagulant therapy: discrete choice experiment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 912-9	5.8	22
182	High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 549-57	2.8	48
181	Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 2008-14	4.7	21
180	Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. <i>Value in Health</i> , <b>2013</b> , 16, 1054-62	3.3	23
179	Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. <i>Osteoporosis International</i> , <b>2013</b> , 24, 237-44	5.3	47
178	The incident user design in comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 1-6	2.6	141
177	Methods for comparative effectiveness research/patient-centered outcomes research: from efficacy to effectiveness. <i>Journal of Clinical Epidemiology</i> , <b>2013</b> , 66, S1-4	5.7	16
176	Improved prediction of medical expenditures and health care utilization using an updated chronic disease score and claims data. <i>Journal of Clinical Epidemiology</i> , <b>2013</b> , 66, 1118-27	5.7	39
175	Adjuvant vancomycin for antibiotic prophylaxis and risk of <i>Clostridium difficile</i> infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2013</b> , 146, 472-8	1.5	10
174	Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. <i>Medical Decision Making</i> , <b>2013</b> , 33, 949-60	2.5	4
173	Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000208	6	17
172	Response letter to Eltonsy and colleagues. <i>Journal of the American Geriatrics Society</i> , <b>2013</b> , 61, 848-9	5.6	
171	Risk of venous thromboembolism in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 1600-7	4.7	57

170	Comment on Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. <i>Statistics in Medicine</i> , <b>2013</b> , 32, 1073-4	2.3	1
169	Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 1239-44	2.6	16
168	Comparative safety of antipsychotic medications in nursing home residents. <i>Journal of the American Geriatrics Society</i> , <b>2012</b> , 60, 420-9	5.6	60
167	Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 239-47	6.1	30
166	Association between the Part D coverage gap and adverse health outcomes. <i>Journal of the American Geriatrics Society</i> , <b>2012</b> , 60, 1408-17	5.6	6
165	The impact of reducing cardiovascular medication copayments on health spending and resource utilization. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1817-24	15.1	46
164	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , <b>2012</b> , 12, 180	4.7	24
163	No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3076-82		26
162	Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. <i>Drug Safety</i> , <b>2012</b> , 35, 407-16	5.1	10
161	Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 480-6	5.8	116
160	Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 697-709	2.6	53
159	An event-based approach for comparing the performance of methods for prospective medical product monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 631-9	2.6	10
158	Response to commentary by Marcus and Gibbons. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 713-2.6		
157	Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 789-96	6.3	47
156	Comment: generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, 303-4; author reply 304	2.9	1
155	Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, e61-4	5.8	1
154	Implications of M bias in epidemiologic studies: a simulation study. <i>American Journal of Epidemiology</i> , <b>2012</b> , 176, 938-48	3.8	54
153	Variation in antipsychotic treatment choice across US nursing homes. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 11-7	1.7	26

152	Medicare part D impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 3-10	1.7	4
151	Beneficiaries with cardiovascular disease and the Part D coverage gap. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 387-95	5.8	17
150	Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 590-6	6	28
149	Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 80-6	6.1	39
148	A combined comorbidity score predicted mortality in elderly patients better than existing scores. <i>Journal of Clinical Epidemiology</i> , <b>2011</b> , 64, 749-59	5.7	548
147	Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 777-90	6.1	137
146	Time series evaluation of an intervention to increase statin tablet splitting by general practitioners. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 235-43	3.5	1
145	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 551-9	2.6	92
144	Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 675-83	2.6	19
143	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 1088-97	2.6	7
142	Accuracy of identifying neutropenia diagnoses in outpatient claims data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 709-13	2.6	7
141	Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 993-1001	6.3	63
140	Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 2525-31	27.4	276
139	Effects of adjusting for instrumental variables on bias and precision of effect estimates. <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 1213-22	3.8	163
138	Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. <i>American Journal of Epidemiology</i> , <b>2011</b> , 173, 1404-13	3.8	132
137	Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 1089-99	3.8	23
136	The effect of altitude change on anemia treatment response in hemodialysis patients. <i>American Journal of Epidemiology</i> , <b>2011</b> , 173, 768-77	3.8	10
135	Availability of comparative efficacy data at the time of drug approval in the United States. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1786-9	27.4	41

134	Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. <i>PLoS Medicine</i> , <b>2011</b> , 8, e1001075	11.6	26
133	Full coverage for preventive medications after myocardial infarction. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2088-97	59.2	484
132	Refilling and switching of antiepileptic drugs and seizure-related events. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 88, 347-53	6.1	57
131	Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1401-9	27.4	162
130	Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. <i>Pediatrics</i> , <b>2010</b> , 125, 876-88	7.4	86
129	The epidemiology of prescriptions abandoned at the pharmacy. <i>Annals of Internal Medicine</i> , <b>2010</b> , 153, 633-40	8	67
128	Comparative mortality risk of anemia management practices in incident hemodialysis patients. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 857-64	27.4	78
127	Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2010</b> , 31, 561-72	9.5	47
126	Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2114-7	2.4	146
125	Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years of data. <i>Archives of General Psychiatry</i> , <b>2010</b> , 67, 497-506		54
124	Confounding control in healthcare database research: challenges and potential approaches. <i>Medical Care</i> , <b>2010</b> , 48, S114-20	3.1	237
123	Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. <i>Medical Care</i> , <b>2010</b> , 48, S83-9	3.1	25
122	Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 848-57	2.6	37
121	Instrumental variable methods in comparative safety and effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 537-54	2.6	229
120	Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 596-603	2.6	120
119	A basic study design for expedited safety signal evaluation based on electronic healthcare data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 858-68	2.6	187
118	Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 1263-75	2.6	48
117	Medicare beneficiaries' knowledge of and choices regarding Part D, 2005 to the present. <i>Journal of the American Geriatrics Society</i> , <b>2010</b> , 58, 950-66	5.6	28

116	Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. <i>Journal of the American Geriatrics Society</i> , <b>2010</b> , 58, 1764-79	5.6	41
115	Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. <i>Journal of Mental Health Policy and Economics</i> , <b>2010</b> , 13, 37-44	1.3	7
114	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. <i>American Journal of Managed Care</i> , <b>2010</b> , 16, 467-71	2.1	90
113	Rosiglitazone and myocardial infarction in patients previously prescribed metformin. <i>PLoS ONE</i> , <b>2009</b> , 4, e6080	3.7	16
112	Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. <i>Circulation</i> , <b>2009</b> , 120, 2322-9	16.7	177
111	Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. <i>Dermatology</i> , <b>2009</b> , 219, 7-21	4.4	60
110	High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. <i>Epidemiology</i> , <b>2009</b> , 20, 512-22	3.1	712
109	Managing drug-risk information--what to do with all those new numbers. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 647-9	59.2	34
108	Antipsychotic agents and sudden cardiac death--how should we manage the risk?. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 294-6	59.2	45
107	Completeness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. <i>Clinical Therapeutics</i> , <b>2009</b> , 31, 2048-59	3.5	20
106	Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. <i>Journal of General Internal Medicine</i> , <b>2009</b> , 24, 570-8	4	26
105	The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. <i>Osteoporosis International</i> , <b>2009</b> , 20, 895-901	5.3	59
104	Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 259-68	2.6	20
103	NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 1134-42	2.6	5
102	Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 253-64	6.1	167
101	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 1226-32	5.7	123
100	Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 1233-41	5.7	91
99	Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. <i>American Heart Journal</i> , <b>2009</b> , 157, 613-9	4.9	5

98	Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. <i>CNS Drugs</i> , <b>2009</b> , 23, 171-80	6.7	18
97	Health advisories and patterns of patient monitoring among new users of antidepressant medications. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 590-4	1.7	
96	Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications. <i>Medical Care</i> , <b>2009</b> , 47, 508-16	3.1	11
95	An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. <i>Medical Care</i> , <b>2009</b> , 47, 1031-5	3.1	16
94	Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. <i>American Journal of Epidemiology</i> , <b>2009</b> , 169, 273-84	3.8	114
93	Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. <i>Journal of the American Geriatrics Society</i> , <b>2008</b> , 56, 1644-50	5.6	78
92	The effect of transitioning to medicare part d drug coverage in seniors dually eligible for medicare and medicaid. <i>Journal of the American Geriatrics Society</i> , <b>2008</b> , 56, 2304-10	5.6	28
91	Aprotinin during coronary-artery bypass grafting and risk of death. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 771-83	59.2	278
90	Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. <i>American Heart Journal</i> , <b>2008</b> , 156, 336-41	4.9	76
89	Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. <i>American Heart Journal</i> , <b>2008</b> , 156, 31-6	4.9	37
88	Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives. <i>Contraception</i> , <b>2008</b> , 78, 399-404	2.5	7
87	The effect of altitude on dosing and response to erythropoietin in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2008</b> , 19, 1389-95	12.7	49
86	The impact of cost sharing on antidepressant use among older adults in British Columbia. <i>Psychiatric Services</i> , <b>2008</b> , 59, 377-83	3.3	13
85	What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings. <i>Journal of General Internal Medicine</i> , <b>2008</b> , 23, 1435-40	4	19
84	Evaluating uses of data mining techniques in propensity score estimation: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2008</b> , 17, 546-55	2.6	140
83	The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 919-28		33
82	Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1754-64		230
81	Developments in post-marketing comparative effectiveness research. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 82, 143-56	6.1	145

80	Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. <i>Cancer Causes and Control</i> , <b>2007</b> , 18, 561-9	2.8	101
79	Statins and the risk of lung, breast, and colorectal cancer in the elderly. <i>Circulation</i> , <b>2007</b> , 115, 27-33	16.7	123
78	Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. <i>Cmaj</i> , <b>2007</b> , 176, 627-32	3.5	260
77	Propensity Score Calibration and its Alternatives. <i>American Journal of Epidemiology</i> , <b>2007</b> , 165, 1122-1123	3.8	13
76	Performance of propensity score calibration--a simulation study. <i>American Journal of Epidemiology</i> , <b>2007</b> , 165, 1110-8	3.8	90
75	Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. <i>Circulation</i> , <b>2007</b> , 115, 2128-35	16.7	96
74	Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. <i>Medical Care</i> , <b>2007</b> , 45, S131-42	3.1	190
73	Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 707-10	1.7	33
72	Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. <i>Medical Care</i> , <b>2007</b> , 45, S158-65	3.1	58
71	Repeated hospitalizations predict mortality in the community population with heart failure. <i>American Heart Journal</i> , <b>2007</b> , 154, 260-6	4.9	361
70	Reference drug programs: effectiveness and policy implications. <i>Health Policy</i> , <b>2007</b> , 81, 17-28	3.2	29
69	Veteran@ affairs hospital discharge databases coded serious bacterial infections accurately. <i>Journal of Clinical Epidemiology</i> , <b>2007</b> , 60, 397-409	5.7	130
68	Understanding secondary databases: a commentary on "Sources of bias for health state characteristics in secondary databases". <i>Journal of Clinical Epidemiology</i> , <b>2007</b> , 60, 648-50	5.7	19
67	Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. <i>American Journal of Managed Care</i> , <b>2007</b> , 13, 445-52	2.1	23
66	Psychotropic medication use for behavioral symptoms of dementia. <i>Current Neurology and Neuroscience Reports</i> , <b>2006</b> , 6, 490-5	6.6	10
65	Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2757-64		189
64	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3390-8		74
63	Patterns of cardiovascular risk in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 1608-12		281

62	Variable selection for propensity score models. <i>American Journal of Epidemiology</i> , <b>2006</b> , 163, 1149-56	3.8	1236
61	Assessing health state utilities in elderly patients at cardiovascular risk. <i>Medical Decision Making</i> , <b>2006</b> , 26, 247-54	2.5	8
60	Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients. <i>Drug Safety</i> , <b>2006</b> , 29, 1077-85	5.1	9
59	Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. <i>Clinical Therapeutics</i> , <b>2006</b> , 28, 964-78; discussion 962-3	3.5	43
58	Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. <i>Journal of Clinical Epidemiology</i> , <b>2006</b> , 59, 18-25	5.7	32
57	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. <i>Journal of Clinical Epidemiology</i> , <b>2006</b> , 59, 819-28	5.7	97
56	Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2006</b> , 15, 291-303	2.6	482
55	Methods in pharmacoepidemiology: time-varying drug effects revisited. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2006</b> , 15, 93-4	2.6	2
54	Angiotensin inhibition after myocardial infarction: does drug class matter?. <i>Journal of General Internal Medicine</i> , <b>2006</b> , 21, 1242-7	4	9
53	A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 379-88	6.1	40
52	A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. <i>Journal of Clinical Epidemiology</i> , <b>2005</b> , 58, 98-102	5.7	58
51	A review of uses of health care utilization databases for epidemiologic research on therapeutics. <i>Journal of Clinical Epidemiology</i> , <b>2005</b> , 58, 323-37	5.7	870
50	Underuse of controller medications among children with persistent asthma in the Ohio medicaid population: evolving differences with new medications. <i>Academic Pediatrics</i> , <b>2005</b> , 5, 83-9		25
49	Risk of death in elderly users of conventional vs. atypical antipsychotic medications. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2335-41	59.2	755
48	Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 427-34	1.7	45
47	Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. <i>Epidemiology</i> , <b>2005</b> , 16, 17-24	3.1	91
46	Suboptimal antidepressant use in the elderly. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 118-26	1.7	37
45	Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. <i>Journal of the American Geriatrics Society</i> , <b>2005</b> , 53, 948-54	5.6	41

44	Identification of individuals with CKD from Medicare claims data: a validation study. <i>American Journal of Kidney Diseases</i> , <b>2005</b> , 46, 225-32	7.4	180
43	Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. <i>American Journal of Kidney Diseases</i> , <b>2005</b> , 46, 1080-7	7.4	60
42	Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. <i>American Journal of Epidemiology</i> , <b>2005</b> , 162, 279-89	3.8	159
41	Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. <i>American Journal of Epidemiology</i> , <b>2005</b> , 161, 891-8	3.8	141
40	Sudden uncontrollable somnolence and medication use in Parkinson disease. <i>Archives of Neurology</i> , <b>2005</b> , 62, 1242-8		58
39	Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. <i>Hypertension</i> , <b>2005</b> , 46, 273-9	8.5	62
38	Performance of a rheumatoid arthritis records-based index of severity. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1679-87	4.1	17
37	Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. <i>Circulation</i> , <b>2004</b> , 109, 2068-73	16.7	414
36	Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. <i>BMJ, The</i> , <b>2004</b> , 328, 560	5.9	53
35	Relationship between COX-2 specific inhibitors and hypertension. <i>Hypertension</i> , <b>2004</b> , 44, 140-5	8.5	117
34	Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2187-94	59.2	100
33	Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. <i>Journal of General Internal Medicine</i> , <b>2004</b> , 19, 444-50	4	72
32	Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 415-20	3	15
31	Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2004</b> , 13, 695-702	2.6	16
30	Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. <i>American Heart Journal</i> , <b>2004</b> , 148, 99-104	4.9	440
29	Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. <i>Annals of Epidemiology</i> , <b>2004</b> , 14, 296-303	6.4	30
28	Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 632-8	1.7	65
27	Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. <i>Medical Care</i> , <b>2004</b> , 42, 653-60	3.1	37

26	Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 74, 388-400	6.1	43
25	Improved comorbidity adjustment for predicting mortality in Medicare populations. <i>Health Services Research</i> , <b>2003</b> , 38, 1103-20	3.4	237
24	Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?. <i>American Journal of Medicine</i> , <b>2003</b> , 115, 715-20	2.4	73
23	Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 273-84	3.5	8
22	Costs of measuring outcomes of acute hospital care in a longitudinal outcomes measurement system. <i>American Journal of Medical Quality</i> , <b>2003</b> , 18, 3-9	1.1	0
21	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. <i>Contemporary Clinical Trials</i> , <b>2002</b> , 23, 757-73		7
20	Prescription duration after drug copay changes in older people: methodological aspects. <i>Journal of the American Geriatrics Society</i> , <b>2002</b> , 50, 521-5	5.6	25
19	Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 285-91	2.8	185
18	Metric properties of the appropriateness evaluation protocol and predictors of inappropriate hospital use in Germany: an approach using longitudinal patient data. <i>International Journal for Quality in Health Care</i> , <b>2002</b> , 14, 483-92	1.9	22
17	Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 822-9	59.2	145
16	Clozapine use and risk of diabetes mellitus. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 236-43	1.7	53
15	On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data. <i>Disease Management and Health Outcomes</i> , <b>2002</b> , 10, 763-769		2
14	Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. <i>Journal of Clinical Epidemiology</i> , <b>2002</b> , 55, 833-41	5.7	31
13	Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. <i>Cmaj</i> , <b>2002</b> , 166, 737-45	3.5	35
12	Pharmaceutical cost containment with reference-based pricing: time for refinements. <i>Cmaj</i> , <b>2002</b> , 167, 1250-1	3.5	5
11	First results from an intensified monitoring system to estimate drug related hospital admissions. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 52, 196-200	3.8	19
10	A case-control study of the effect of infant feeding on celiac disease. <i>Annals of Nutrition and Metabolism</i> , <b>2001</b> , 45, 135-42	4.5	56
9	Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. <i>American Journal of Epidemiology</i> , <b>2001</b> , 154, 854-64	3.8	554

8	On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. <i>Health Policy</i> , <b>2001</b> , 55, 97-109	3.2	29
7	Sensitivity analysis of the diagnostic value of endoscopies in cross-sectional studies in the absence of a gold standard. <i>International Journal of Technology Assessment in Health Care</i> , <b>2000</b> , 16, 834-41	1.8	3
6	Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. <i>Chest</i> , <b>2000</b> , 117, 870-4	5.3	157
5	Use of comorbidity scores for control of confounding in studies using administrative databases. <i>International Journal of Epidemiology</i> , <b>2000</b> , 29, 891-8	7.8	305
4	What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. <i>Health Policy</i> , <b>1998</b> , 44, 253-60	3.2	32
3	Internet Surveys by Direct Mailing: An Innovative Way of Collecting Data. <i>Social Science Computer Review</i> , <b>1997</b> , 15, 242-255	3.1	54
2	Measurement error correction for logistic regression models with an "alloyed gold standard". <i>American Journal of Epidemiology</i> , <b>1997</b> , 145, 184-96	3.8	107
1	Effectiveness of the Single-Dose Ad26.COVID.2.S COVID Vaccine		9